Email this article Clinical case long-term care of the patient with mCRPC
- Authors: Zaborskiy IN1, Karjakin OB1
-
Affiliations:
- Medical Radiology Centre of Hertsen FMRC MH RF A.Cyb - Scientific Research Centre of Radiology of the Hertsen Federal Medical Research Centre of the Ministry of Health of the Russian Federation (Medical Radiology Centre of Hertsen FMRC MH RF). 10, Zhukov street, Obninsk, 249036, Kaluga region, Russia
- Issue: Vol 16, No 4 (2014)
- Pages: 58-60
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26983
- ID: 26983
Cite item
Full Text
Abstract
Patients with metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis, and those patients with metastases areexpected to survive ≤19 mo. As patientsʼ disease progresses, quality of life deteriorates, and until recently, few treatment options were available. Several new therapies have shown an improvement in overall survival for patients with mCRPC who have already received chemotherapy with docetaxel. The impact of these new data on daily clinical practice, treatment sequencing, and best care for individual patients is not yet fully understood. Early detection of castration resistance before the development of clinical symptoms and significant prevalence of tumor gives patients the opportunity to receive as many lines of drug therapy with a satisfactory quality of life, which, of course, leads to an increase in overall survival. Here we present clinical case long-term care of the patient with mCRPC.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
I N Zaborskiy
Medical Radiology Centre of Hertsen FMRC MH RF A.Cyb - Scientific Research Centre of Radiology of the Hertsen Federal Medical Research Centre of the Ministry of Health of the Russian Federation (Medical Radiology Centre of Hertsen FMRC MH RF). 10, Zhukov street, Obninsk, 249036, Kaluga region, Russia
Email: i.zaborskii@mail.ru
ординатор отд-ния лучевого и хирургического лечения урологических заболеваний с группой брахитерапии рака предстательной железы
O B Karjakin
Medical Radiology Centre of Hertsen FMRC MH RF A.Cyb - Scientific Research Centre of Radiology of the Hertsen Federal Medical Research Centre of the Ministry of Health of the Russian Federation (Medical Radiology Centre of Hertsen FMRC MH RF). 10, Zhukov street, Obninsk, 249036, Kaluga region, Russia
Email: karyakin@mrrc.obninsk.ru
д-р мед. наук, проф., рук. отд-ния лучевого и хирургического лечения урологических заболеваний с группой брахитерапии рака предстательной железы
References
- Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 г. М., 2015.
- Чиссов В.И., Русаков И.Г. Experimental & Clinical urology. Заболеваемость раком предстательной железы в Российской Федерации. 2011; 2-3.
- Алексеев Б.Я., Русаков И.Г., Сивков А.В. UMP (Universal Medical Portal). Новые подходы к диагностике и лечению кастрационно - резистентного рака предстательной железы. Онкология, гематология и радиология. 2014; 4: 48-59.
- Новости медицины и фармации. Ремедиум. Новая схема лечения рака предстательной железы от 07.08.2012.
- Stanbrough M, Bubley G.J, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen - independent prostate cancer. Cancer Res 2006; 66 (5): 2815-25; http://www.ncbi.nlm.nih.gov/ pubmed/16510604
- European Association of Urology (EAU). Guidelines 2014; pp. 154-63.
- European Association of Urology (EAU). Guidelines 2014. Table 20.3. Randomised controlled trials - drug treatment of CRPC; p. 159.
- Bono de J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
- Fizazi K, Scher H.I, Molina A. Abiraterone acetate for treatment of metastatic castration - resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double - blind, placebo - controlled phase 3 study. Lancet Oncology 2012; 13 (10): 983-99.
- Berthold D.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
- Ryan C et al. ESMO 2014. Abstr. 7530 (oral presentation).
- Scher H.I, Halabi S, Tannock I et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26 (7): 1148-59; http://www.ncbi.nlm.nih.gov/ pubmed/18309951
